【摘要】 目的　评价去甲长春花碱 (vinorelbine ,NVB)联合顺铂 (cisplatin ,DDP)治疗非小细胞肺癌的近期疗效、毒副反应、中位生存期及生存率。方法　对 2 2 0例不能手术的非小细胞肺癌患者采用NVB联合DDP化疗 ,NVB 2 5～ 3 0mg/(m2 ·d) ,第 1、5 (或第 8)天 ;DDP 60～ 80mg/(m2 ·d) ,第 2天 ,2 8天为一周期。完成两周期以上评价疗效 ,观察毒副反应并进行随访。结果　全组有效率 (RR)为 3 0 .9% ( 68/2 2 0 ) ,初治者有效率为 3 1.3 % ( 5 1/163 ) ,复治者为 2 9.8% ( 17/5 7)。全组中位生存期 8.3月 ,1年生存率 3 9.2 3 % ,2年生存率 19.3 1% ,3年生存率 6.3 2 %。主要毒性反应为骨髓抑制和消化道反应。结论　NVB联合DDP是治疗非小细胞肺癌有效且耐受性好的方案 ,骨髓抑制为其剂量限制性毒性。更多还原

【Abstract】 Objective To evaluate the efficacy, side effects, median survival duration and survival rate of vinorelbine (NVB) combined with cisplatin (DDP) in the treatment of non small cell lung cancer (NSCLC). Methods A total of 220 patients with inoperable NSCLC received NVB and DDP combined chemotherapy: NVB 25 30 mg/(m 2·d) on days 1 and 5 (or 8), DDP 60 80 mg/(m 2·d) on day 2. The schedule was repeated every 28 days. The efficacy and side effects were analysed and followed up after at least two cycles of chemotherapy. Results The overall response rate (CR+PR) was 30.9% (68/220). The response rate was 31.3% (51/163) in initial treatment group, and 29.8% (17/57) in retreatment group. The median survival duration was 8.3 months. The 1 , 2 and 3 year survival rates were 39.23%, 19.31% and 6.32%, respectively. The main side effects were myelosuppression and digestive tract reactions. Conclusion Vinorelbine plus cisplatin is an effective and well tolerated regimen for non small cell lung cancer and myelosuppression is its dose limiting toxicity.更多还原